Safety, Efficacy and Tolerability of Vilazodone in Generalized Anxiety Disorder (VLZ-MD-05)

December 4, 2019 updated by: Forest Laboratories

A Double-blind, Placebo-Controlled Fixed-Dose Study of Vilazodone in Patients With Generalized Anxiety Disorder.

The purpose of this study is to evaluate the efficacy, safety and tolerability of vilazodone relative to placebo in the treatment of generalized anxiety disorder (GAD)

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

680

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • Alabama
      • Birmingham, Alabama, United States, 35216
        • Forest Investigative Site 001
    • California
      • Beverly Hills, California, United States, 90210
        • Forest Investigative Site 021
      • Glendale, California, United States, 91204
        • Forest Investigative Site 023
      • Paramount, California, United States, 90723
        • Forest Investigative Site 011
    • Connecticut
      • Norwich, Connecticut, United States, 06360
        • Forest Investigative Site 026
      • Waterbury, Connecticut, United States, 06708
        • Forest Investigative Site 027
    • Florida
      • Delray Beach, Florida, United States, 33484
        • Forest Investigative Site 005
      • Oakland Park, Florida, United States, 33334
        • Forest Investigative Site 014
      • South Miami, Florida, United States, 33143
        • Forest Investigative Site 019
    • Georgia
      • Atlanta, Georgia, United States, 30328
        • Forest Investigative Site 038
      • Decatur, Georgia, United States, 30030
        • Forest Investigative Site 035
    • Illinois
      • Chicago, Illinois, United States, 60634
        • Forest Investigative Site 028
      • Schaumburg, Illinois, United States, 60194
        • Forest Investigative Site 030
    • Kansas
      • Topeka, Kansas, United States, 66606
        • Forest Investigative Site 029
      • Wichita, Kansas, United States, 67207
        • Forest Investigative Site 033
    • Louisiana
      • Lake Charles, Louisiana, United States, 70629
        • Forest Investigative Site 010
    • Maryland
      • Baltimore, Maryland, United States, 21208
        • Forest Investigative Site 031
    • Massachusetts
      • Boston, Massachusetts, United States, 02114
        • Forest Investigative Site 025
    • Missouri
      • Saint Louis, Missouri, United States, 63104
        • Forest Investigative Site 037
    • Nevada
      • Las Vegas, Nevada, United States, 89103
        • Forest Investigative Site 015
    • New Jersey
      • Berlin, New Jersey, United States, 08009
        • Forest Investigative Site 016
    • New York
      • Brooklyn, New York, United States, 11235
        • Forest Investigative Site 007
      • New York, New York, United States, 10003
        • Forest Investigative Site 024
      • New York, New York, United States, 10023
        • Forest Investigative Site 032
      • New York, New York, United States, 10168
        • Forest Investigative Site 012
    • North Dakota
      • Bismarck, North Dakota, United States, 58501
        • Forest Investigative Site 020
    • Ohio
      • Cincinnati, Ohio, United States, 45215
        • Forest Investigative Site 008
      • Dayton, Ohio, United States, 45414
        • Forest Investigative Site 041
    • Oklahoma
      • Oklahoma City, Oklahoma, United States, 73112
        • Forest Investigative Site 004
      • Oklahoma City, Oklahoma, United States, 73116
        • Forest Investigative Site 034
    • Oregon
      • Portland, Oregon, United States, 97210
        • Forest Investigative Site 013
    • Tennessee
      • Memphis, Tennessee, United States, 38119
        • Forest Investigative Site 006
    • Texas
      • Wichita Falls, Texas, United States, 76309
        • Forest Investigative Site 017
    • Utah
      • Salt Lake City, Utah, United States, 84106
        • Forest Investigative Site 003
    • Virginia
      • Charlottesville, Virginia, United States, 22911
        • Forest Investigative Site 018
    • Washington
      • Bellevue, Washington, United States, 98007
        • Forest Investigative Site 040
      • Seattle, Washington, United States, 98104
        • Forest Investigative Site 039

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 70 years (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Male and female, 18 - 70 years of age
  • Currently meet the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) criteria for Generalized Anxiety Disorder (GAD)
  • Minimum score of 20 on the Hamilton Rating Scale for Anxiety (HAM-A)

Exclusion Criteria:

  • Women who are pregnant, women who will be breastfeeding during the study and women of childbearing potential who are not practicing a reliable method of birth control

  • History of meeting DSM-IV-TR criteria for any of the following:

    • Any manic or hypomanic or mixed episode, including bipolar disorder and substance-induced manic, hypomanic or mixed episode
    • Any depressive episode with psychotic or catatonic features
    • Panic disorder with or without agoraphobia
    • Obsessive-compulsive disorder
    • Schizophrenia, schizoaffective, or other psychotic disorder
    • Bulimia or anorexia nervosa
    • Presence of borderline personality disorder or antisocial personality disorder
    • Mental retardation, dementia, amnesia, or other significant cognitive disorders
  • Patients who are considered a suicide risk

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: TREATMENT
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: TRIPLE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
PLACEBO_COMPARATOR: Placebo
Dose-matched placebo one per day, oral administration
Drug: Placebo
Matching 10 mg and 20 mg placebo tablets, once per day, oral administration,
EXPERIMENTAL: Vilazadone 20mg
Vilazodone 20mg once per day, oral administration.
Drug: Vilazodone
Vilazodone, 20mg, oral administration once per day.
Drug: Vilazodone
Vilazodone, 40mg, oral administration once per day.
EXPERIMENTAL: Vilazodone 40mg
Vilazodone 40mg once per day, oral administration
Drug: Vilazodone
Vilazodone, 20mg, oral administration once per day.
Drug: Vilazodone
Vilazodone, 40mg, oral administration once per day.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change From Baseline in the Hamilton Rating Scale for Anxiety (HAM-A) Total Score
Time Frame: Baseline to Week 8
The Hamilton Anxiety Rating Scale (HAM-A) is a clinician-administered scale which consists of 14 items, each rated on a five point scale ranging from 0 (not present) to 4 (very severe). The highest possible score is 56, which represents the most severe form of anxiety; the lowest possible score is 0, which represents an absence of anxiety.
Baseline to Week 8

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change From Baseline in the Sheehan Disability Scale (SDS) Total Score
Time Frame: Baseline to Week 8
The Sheehan Disability Scale (SDS) is a 3-item clinician-rated questionnaire used to evaluate impairments in the domains of work, social life/leisure, and family life/home responsibility. All items are rated on an 11-point continuum (0 = no impairment to 10 = most severe) with the total SDS score ranging from 0 (no impairment) to 30 (most severe).
Baseline to Week 8

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Forest Laboratories

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

June 30, 2012

Primary Completion (ACTUAL)

February 28, 2014

Study Completion (ACTUAL)

March 31, 2014

Study Registration Dates

First Submitted

June 26, 2012

First Submitted That Met QC Criteria

June 27, 2012

First Posted (ESTIMATE)

June 28, 2012

Study Record Updates

Last Update Posted (ACTUAL)

December 18, 2019

Last Update Submitted That Met QC Criteria

December 4, 2019

Last Verified

November 1, 2019

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • VLZ-MD-05

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Generalized Anxiety Disorder

Clinical Trials on Placebo

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cameroon

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe